3E: 3,200+ Regulatory Lists—But Which Changes Matter to Your Pharma Portfolio?

Overview: How 3E’s AI-Driven Regulatory Intelligence Platform Transforms Pharma Chemical Compliance

3E is a regulatory intelligence provider that combines expert-curated chemical and product data with software and AI-enabled capabilities to support pharmaceutical operations. Its offering addresses a persistent information bottleneck: relevant updates, substance information, and supplier documents are often spread across disconnected sources. Bringing these resources into portfolio-specific workflows can make it easier to identify material changes and assess their implications without repeatedly searching broad information feeds.

The portfolio combines data services, monitoring tools, and enterprise integrations rather than functioning as a single AI application. 3E Insight filters and contextualises information against a company’s products, while its Regulatory Intelligence API makes chemical data available within existing systems. Selected capabilities add automation: the Supplier SDS Loader extracts and validates information from supplier safety data sheets, and 3E Generate uses product composition data, curated content, and expert-approved logic to assemble standardised documents. These functions complement specialist interpretation rather than replace it.

The practical value lies in reducing repetitive data handling and improving access to decision-relevant information. Embedded data can reduce switching between systems, while automated extraction can shorten document-processing work; 3E reports up to a 70% reduction in manual effort for its Supplier SDS Loader. ,That figure is vendor-reported and specific to this capability, not a measured improvement across the entire platform.

Last checked on November 9, 2026: 3E’s pharmaceuticals page highlights an October 26 update to Exchange featuring embedded agentic AI for supplier-data collection and compliance workflows.

What is 3E?

3E provides regulatory intelligence and chemical-safety software for pharmaceutical companies, supporting regulatory-change monitoring, safety data sheet management, chemical inventory oversight, and product stewardship. Its products serve regulatory affairs, R&D, environmental health and safety, and sustainability teams rather than clinical decision-making workflows. Its technical approach combines expert-curated regulatory content with portfolio-specific monitoring, API and SAP integrations, and AI-enabled capabilities across selected products, including automated supplier safety data sheet extraction and validation.

Intended Use and Limitations

• 3E announced ISO/IEC 42001:2023 certification in August 2026 following an audit by Prescient Security; it covers AI management processes, not individual products, models, or output accuracy.

• 3E’s Trust Center lists SOC 2 Type II assurance for its products; buyers should obtain the report to verify covered services, audit period, and exceptions.

• 3E states GDPR compliance and annual certification under the EU–U.S., UK, and Swiss–U.S. Data Privacy Framework arrangements; these statements do not establish suitability for processing protected health information.

• Its information-security program follows ISO 27001 and NIST frameworks, but the reviewed documentation does not establish ISO 27001 certification.

• Published security controls include AES-256 encryption at rest, encrypted transmission, least-privilege access, and quarterly third-party cybersecurity risk assessments.

• 3E explicitly states that its AI-management certification neither guarantees correct AI-generated answers nor establishes EU AI Act compliance, preserving the need for use-case-specific validation and human review.

• New Mountain Capital and Endicott Capital acquired 3E from Verisk in March 2022, with New Mountain as the controlling investor; this establishes its ownership history, not a guarantee of financial stability.

• 3E’s July 2026 acquisition of Yordas Group expanded its scientific expertise, regulatory content, and chemical-registration services relevant to pharmaceutical product stewardship.

• Verdantix named 3E a Leader in its 2026 supply-chain sustainability software assessment, following a 2025 product-compliance Leader position; these recognitions concern enterprise software, not clinical effectiveness.